Comprehensive molecular characterization of gastric adenocarcinoma
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Gastric cancer is a leading cause of cancer deaths, but analysis of its molecular and clinical characteristics has been complicated by histological and aetiological heterogeneity. Here we describe a comprehensive molecular evaluation of 295 primary gastric adenocarcinomas as part of The Cancer Genome Atlas (TCGA) project. We propose a molecular classification dividing gastric cancer into four subtypes: tumours positive for Epstein–Barr virus, which display recurrent PIK3CA mutations, extreme DNA hypermethylation, and amplification of JAK2, CD274 (also known as PD-L1) and PDCD1LG2 (also known as PD-L2); microsatellite unstable tumours, which show elevated mutation rates, including mutations of genes encoding targetable oncogenic signalling proteins; genomically stable tumours, which are enriched for the diffuse histological variant and mutations of RHOA or fusions involving RHO-family GTPase-activating proteins; and tumours with chromosomal instability, which show marked aneuploidy and focal amplification of receptor tyrosine kinases. Identification of these subtypes provides a roadmap for patient stratification and trials of targeted therapies. The Cancer Genome Atlas reports on molecular evaluation of 295 primary gastric adenocarcinomas and proposes a new classification of gastric cancers into 4 subtypes, which should help with clinical assessment and trials of targeted therapies. This contribution from The Cancer Genome Atlas (TCGA) project describes the molecular evaluation of 295 primary gastric adenocarcinomas. Based on the results, the authors propose a novel classification separating gastric cancers into four subtypes according to: Epstein–Barr virus positive status, microsatellite instability, chromosomal instability or genomic stability. Given the histologic and etiologic heterogeneity of gastric cancer identification of these subtypes, using a schema that can readily be applied to patient samples should help with patient stratification and trials of targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many of the miRNAs were also reported by a recent systems biology paper from TCGA in 2014 [34].”
From Bioinformatic Interrogation of 5p-arm and 3p-arm Specific miRNA Expression Using TCGA Datasets (2015) · cites this paper as [34]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The fusion of this evidence has prompted TCGA and the Asian Cancer Research Group (ACRG) to propose several molecular classifications [77,78].”
From Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer (2024) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“The TP53/APC double knockout (DKO) organoid line was established in our previous studies by sequentially disrupting TP53 and APC37, two common oncogenic loci in gastric adenocarcinoma38,39, from non-neoplastic human gastric organoids (Fig. S1A).”
From Large-scale CRISPR screening in primary human 3D gastric organoids enables comprehensive dissection of gene-drug interactions (2025) · cites this paper as [38]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Fusobacterium spp. is important in the development and progression of gastrointestinal tumors1,19,34,35”
From RETRACTED ARTICLE: Microbiome analyses of blood and tissues suggest cancer diagnostic approach (2020) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Self-citationLAURÉN, P. (1965) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/apm.1965.64.1.31 · Cited by 6,133
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationWHO Classification of Tumours of the Digestive System
Bosman, F. T. (2010) · Medical Entomology and Zoology · Cited by 5,041
Cell Migration: Integrating Signals from Front to Back
Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy, G., Parsons, J. T., & Horwitz, A. R. (2003) · Science · doi:10.1126/science.1092053 · Cited by 4,978
Helicobacter pylori Infection and the Development of Gastric Cancer
Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., Sasaki, N., & Schlemper, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa001999 · Cited by 4,465
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
Research works printed but not linked: 2
- Ferlay, J. et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide. IARC CancerBase 11, http://globocan.iarc.fr, accessed on January 15, 2014 (2013)
- The Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012) · DOI · Paper page
Cited by
Items 701–800 of 1,024
Wang, Z., Wang, X., Xu, Y., Li, J., Zhang, X., Peng, Z., Hu, Y., Zhao, X., Dong, K., Zhang, B., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02327-y · Cited by 90
Sugano, K., Spechler, S. J., El-Omar, E. M., McColl, K. E. L., Takubo, K., Gotoda, T., Fujishiro, M., Iijima, K., Inoue, H., Kawai, T., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-327281 · Cited by 88
Is signet-ring cell carcinoma a specific entity among gastric cancers?
Voron, T., Messager, M., Duhamel, A., Lefèvre, J. H., Mabrut, J., Goèré, D., Meunier, B., Brigand, C., Hamy, A., Gléhen, O., et al. (2015) · Gastric Cancer · doi:10.1007/s10120-015-0564-2 · Cited by 82
PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
Šmahel, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061331 · Cited by 90
Kuboki, Y., Yamashita, S., Niwa, T., Ushijima, T., Nagatsuma, A. K., Kuwata, T., Yoshino, T., Doi, T., Ochiai, A., & Ohtsu, A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv508 · Cited by 88
Krause, L., Nones, K., Loffler, K. A., Nancarrow, D. J., Oey, H., Tang, Y., Wayte, N., Patch, A., Patel, K., Brosda, S., et al. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw018 · Cited by 117
Tumor diversity and the trade-off between universal cancer tasks
Hausser, J., Székely, P., Bar, N., Zimmer, A., Sheftel, H., Caldas, C., & Alon, U. (2019) · Nature Communications · doi:10.1038/s41467-019-13195-1 · Cited by 87
Du, Y., Lin, Y., Gan, L., Wang, S., Chen, S., Li, C., Hou, S., Hu, B., Wang, B., Ye, Y., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04688-1 · Cited by 98
“The National Cancer Institute released the TCGA Subtypes for Gastric Cancer in 2014 [34].”
BackgroundMethodNeoadjuvant therapy for gastric cancer: current evidence and future directions.
Newton, A. D., Datta, J., Loaiza‐Bonilla, A., Karakousis, G. C., & Roses, R. E. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2015.047 · Cited by 87
Smith, J. P., Nadella, S., & Osborne, N. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.03.004 · Cited by 91
PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer
Wu, Y., Cao, D., Qu, L., Cao, X., Jia, Z., Zhao, T., Wang, Q., & Jiang, J. (2017) · Oncotarget · doi:10.18632/oncotarget.19318 · Cited by 82
Li, Y., Xu, C., Wang, B., Xu, F., Ma, F., Qu, Y., Jiang, D., Li, K., Feng, J., Tian, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33282-0 · Cited by 80
Self-citationCo-infection of Epstein-Barr virus and human papillomavirus in human tumorigenesis
Shi, Y., Peng, S., Yang, L., Chen, X., Tao, Y., & Cao, Y. (2016) · 癌症:英文版 · doi:10.1186/s40880-016-0079-1 · Cited by 89
Integrative clustering methods of multi‐omics data for molecule‐based cancer classifications
Wang, D., & Gu, J. (2016) · Quantitative Biology · doi:10.1007/s40484-016-0063-4 · Cited by 80
Comparison and applicability of molecular classifications for gastric cancer
Serra, O., Galán, M., Ginesta, M. M., Calvo, M., Sala, N., & Salazar, R. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.05.005 · Cited by 106
Wu, X., Qu, D., Weygant, N., Peng, J., & Houchen, C. W. (2020) · Cancers · doi:10.3390/cancers12020274 · Cited by 83
Sierra, J. C., Piazuelo, M. B., Luis, P. B., Barry, D. P., Allaman, M. M., Asim, M., Sebrell, T. A., Finley, J. L., Rose, K. L., Hill, S., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1304-6 · Cited by 82
Gastric cancer and genomics: review of literature
Onoyama, T., Ishikawa, S., & Isomoto, H. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-022-01879-3 · Cited by 97
“Most diffuse-type GC, known as the histopathological classification of GC with poor prognosis, corresponds to the GS subgroup in the molecular subtypes via genomic analysis and has low-frequency structural chromosome aberration and gene mutations that could be targets for treatment [12].”
BackgroundInfluentialLiu, H., Fang, D., Zhang, C., Zhao, Z., Liu, Y., Zhao, S., Zhang, N., & Xu, J. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.04.013 · Cited by 85
“6 Therefore, protein phosphatase 2A (PP2A), one of the major serine-threonine phosphatases negatively regulating PI3K-AKT and MAPK pathways, has been widely designated as a tumor suppressor.”
Digestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 100
Ali, S. M., Sanford, E. M., Klempner, S. J., Rubinson, D. A., Wang, K., Palma, N. A., Chmielecki, J., Yelensky, R., Palmer, G. A., Morosini, D., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0378 · Cited by 83
Takahashi, N., Iwasa, S., Sasaki, Y., Shoji, H., Honma, Y., Takashima, A., Okita, N. T., Kato, K., Hamaguchi, T., & Yamada, Y. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2184-6 · Cited by 88
Challenges of deciphering gastric cancer heterogeneity
Hudler, P. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i37.10510 · Cited by 86
Apatinib for the treatment of gastric cancer
Roviello, G., Ravelli, A., Fiaschi, A. I., Cappelletti, M. R., Gobbi, A., Senti, C., Zanotti, L., Połom, K., Reynolds, A. R., Fox, S. B., et al. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2016.1209407 · Cited by 85
Analysis of Epstein-Barr Virus Genomes and Expression Profiles in Gastric Adenocarcinoma
Borozan, I., Zapatka, M., Frappier, L., & Ferretti, V. (2017) · Journal of Virology · doi:10.1128/jvi.01239-17 · Cited by 92
Matsuoka, T., & Yashiro, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115880 · Cited by 83
“The fusion of this evidence has prompted TCGA and the Asian Cancer Research Group (ACRG) to propose several molecular classifications [77,78].”
BackgroundMicroRNA-335-5p is a potential suppressor of metastasis and invasion in gastric cancer
Sandoval, A., Polakovičová, I., Carrasco-Véliz, N., Lobos‐González, L., Riquelme, I., Carrasco-Aviño, G., Bizama, C., Norero, E., Owen, G. I., Roa, J. C., et al. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0413-8 · Cited by 88
“Although comprehensive studies have identified several genes associated with the development and progression of gastric cancer, the detailed molecular mechanisms of the disease still remain poorly understood [3, 4].”
BackgroundEBV and Apoptosis: The Viral Master Regulator of Cell Fate?
Fitzsimmons, L., & Kelly, G. L. (2017) · Viruses · doi:10.3390/v9110339 · Cited by 87
Polakovičová, I., Jerez, S., Wichmann, I. A., Sandoval, A., Carrasco-Véliz, N., & Corvalán, A. H. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00636 · Cited by 85
“Several morphological and novel molecular classifications have been developed for the comprehensive characterization of GC (Hamilton and Aaltonen, 2000; The Cancer Genome Atlas Research Network, 2014).”
BackgroundInfluentialTargeted and novel therapy in advanced gastric cancer
Selim, J. H., Shaheen, S., Sheu, W.-C., & Hsueh, C.-T. (2019) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0149-6 · Cited by 87
MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy
Rodriquenz, M. G., Roviello, G., D’Angelo, A., Lavacchi, D., Roviello, F., & Połom, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051427 · Cited by 96
Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
Lü, Z., Peng, Z., Liu, C. X., Wang, Z., Wang, Y., Jiao, X., Li, J., & Shen, L. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100041 · Cited by 91
Rho GTPases: Big Players in Breast Cancer Initiation, Metastasis and Therapeutic Responses
Humphries, B. A., Wang, Z., & Yang, C. (2020) · Cells · doi:10.3390/cells9102167 · Cited by 83
Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review
Zheng, J., Zhang, W., Li, L., He, Y., Wei, Y., Dang, Y., Nie, S., & Guo, Z. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.860985 · Cited by 81
Lin, Q., Wang, X., & Hu, Y. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216318 · Cited by 78
Huang, T., Kang, W., Zhang, B., Wu, F., Dong, Y., TONG, J. H. M., Yang, W., Zhou, Y., Zhang, L., Cheng, A. S. L., et al. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0493-7 · Cited by 79
Targeting CLDN18.2 in cancers of the gastrointestinal tract: new drugs and new indications
Chen, J., Xu, Z., Hu, C., Zhang, S., Zi, M., Yuan, L., & Cheng, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1132319 · Cited by 78
Gastric Cancer Genomics: Advances and Future Directions
Katona, B. W., & Rustgi, A. K. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.01.003 · Cited by 78
Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress
Myint, Z. W., & Goel, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0454-7 · Cited by 81
Transmembrane helix connectivity in Orai1 controls two gates for calcium-dependent transcription
Frischauf, I., Litviňuková, M., Schober, R., Zayats, V., Svobodová, B., Bonhenry, D., Lunz, V., Cappello, S., Tociu, L., Řeha, D., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aao0358 · Cited by 81
MicroRNA Expression Profiles in Gastric Carcinogenesis
Hwang, J., Min, B., Jang, J., Kang, S. Y., Bae, H., Jang, S. S., Kim, J., & Kim, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-32782-8 · Cited by 78
Identification and characterization of an alternative cancer-derived PD-L1 splice variant
Hassounah, N. B., Malladi, V. S., Huang, Y., Freeman, S. S., Beauchamp, E. M., Koyama, S., Souders, N. C., Martin, S., Dranoff, G., Wong, K., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2284-z · Cited by 84
Poirion, O., Zhu, X., Ching, T., & Garmire, L. X. (2018) · Nature Communications · doi:10.1038/s41467-018-07170-5 · Cited by 78
Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives
Abdul-Latif, M., Townsend, K., Dearman, C., Shiu, K.-K., & Khan, K. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102030 · Cited by 77
Genetic characteristics of gastric-type mucinous carcinoma of the uterine cervix
Park, E., Kim, S. W., Kim, S., Kim, H.-S., Lee, J., Kim, Y. T., & Cho, N. H. (2020) · Modern Pathology · doi:10.1038/s41379-020-0614-0 · Cited by 88
Martínez, V. D., Enfield, K. S. S., Rowbotham, D. A., & Lam, W. L. (2015) · Gastric Cancer · doi:10.1007/s10120-015-0487-y · Cited by 79
Sox2 Suppresses Gastric Tumorigenesis in Mice
Sarkar, A., Huebner, A. J., Sulahian, R., Anselmo, A. N., Xu, X., Flattery, K., Desai, N., Sebastián, C., Yram, M. A., Arnold, K., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.034 · Cited by 82
CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma
Zhou, J. R., Wu, Z., Wong, G. S., Pectasides, E., Nagaraja, A. K., Stachler, M. D., Zhang, H., Chen, T., Zhang, H., Liu, J. B., et al. (2017) · Nature Communications · doi:10.1038/ncomms13897 · Cited by 86
Gao, M., Lin, M., Rao, M., Thompson, H., Hirai, K., Choi, M., Georgakis, G. V., Sasson, A. R., Bucobo, J. C., Tzimas, D. J., et al. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6662-8 · Cited by 88
Implementation of gastric cancer screening – The global experience
Leja, M., You, W., Camargo, M. C., & Saito, H. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.09.005 · Cited by 79
Wang, L., Yin, J., Wang, X., Shao, M., Duan, F., Wu, W., Peng, P., Jin, J., Tang, Y., Ruan, Y., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.034 · Cited by 77
Yamamoto, H., & Imai, K. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.08.003 · Cited by 86
Molecular profiling of EBV associated diffuse large B-cell lymphoma
Frontzek, F., Staiger, A. M., Stelmach, R., Grau, M., Zapukhlyak, M., Kurz, K. S., Horn, H., Erdmann, T., Fend, F., Richter, J., et al. (2023) · Leukemia · doi:10.1038/s41375-022-01804-w · Cited by 89
Comprehensive characterization of the genomic alterations in human gastric cancer
Cui, J., Yin, Y., Ma, Q., Wang, G., Olman, V. N., Zhang, Y., Chou, W., Hong, C. S., Zhang, C., Cao, S., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29352 · Cited by 78
Fang, W., Huang, K., Lan, Y., Lin, C., Chang, S., Chen, M., Chao, Y., Lin, W., Lo, S.-S., Li, A. F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6641 · Cited by 81
The structure and regulation of the E3 ubiquitin ligase HUWE1 and its biological functions in cancer
Gong, X., Du, D., Deng, Y., Zhou, Y., Sun, L., & Yuan, S. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00894-6 · Cited by 91
Giampieri, R., Maccaroni, E., Mandolesi, A., Prete, M. D., Andrikou, K., Faloppi, L., Bittoni, A., Bianconi, M., Scarpelli, M., Bracci, R., et al. (2016) · Gastric Cancer · doi:10.1007/s10120-016-0594-4 · Cited by 86
Ungerleider, N., Jain, V., Wang, Y., Maness, N. J., Blair, R. V., Alvarez, X. A., Midkiff, C. C., Kolson, D. L., Bai, S., Roberts, C., et al. (2018) · Journal of Virology · doi:10.1128/jvi.01952-18 · Cited by 77
Targeting the PD-1 pathway: a new hope for gastrointestinal cancers
Bilgin, B., Sendur, M. A. N., Bülent Akıncı, M., Şener Dede, D., & Yalçın, B. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1279132 · Cited by 75
Koi, M., Okita, Y., & Carethers, J. M. (2018) · Journal of the Anus Rectum and Colon · doi:10.23922/jarc.2017-055 · Cited by 85
The Pattern of Signatures in Gastric Cancer Prognosis
Machlowska, J., Maciejewski, R., & Sitarz, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061658 · Cited by 77
“in advanced GC with Epstein-Barr virus positive patients, can be applied to the PIK3CA/Akt pathway, JAK2 and PD-1/PD-L1, and PD-L2 pathway [22].”
BackgroundInfluentialKanda, T. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-7230-7_17 · Cited by 75
Barrett, M. T., Lenkiewicz, E., Malasi, S., Basu, A., Yearley, J. H., Annamalai, L., McCullough, A. E., Kosiorek, H., Narang, P., Sayres, M. A. W., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1004-0 · Cited by 77
A DNA methylation signature to improve survival prediction of gastric cancer
Peng, Y., Wu, Q., Wang, L., Wang, H., & Yin, F. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-0807-x · Cited by 82
Luo, D., Liu, Y., Lu, Z., & Huang, L. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01075-y · Cited by 112
The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment
Gru, A. A., Haverkos, B. M., Freud, A. G., Hastings, J., Nowacki, N. B., Barrionuevo, C., Vigil, C. E., Rochford, R. A., Natkunam, Y., Baiocchi, R. A., et al. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0292-z · Cited by 75
Raufi, A. G., & Klempner, S. J. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2015.037 · Cited by 91
Colorectal Cancer Subtypes: Developmental Origin and Microenvironmental Regulation
Fessler, E., & Medema, J. P. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.07.008 · Cited by 92
BRD4 regulates cellular senescence in gastric cancer cells via E2F/miR-106b/p21 axis
Dong, X., Hu, X., Chen, J., Hu, D., & Chen, L.-F. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0181-6 · Cited by 75
Cho, J., Chang, Y. H., Heo, Y. J., Kim, S., Kim, N. K. D., Park, J. O., Kang, W. K., Lee, J., & Kim, K. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000326 · Cited by 81
DUSP1 induces apatinib resistance by activating the MAPK pathway in gastric cancer
Teng, F., Xu, Z., Chen, J., Zheng, G., Zheng, G., Lv, H., Wang, Y., Wang, L., & Cheng, X. (2018) · Oncology Reports · doi:10.3892/or.2018.6520 · Cited by 87
“Previous studies have supported the inhibition of angiogenesis in GC (11).”
Birkman, E., Mansuri, N., Kurki, S. H., Ålgars, A., Lintunen, M., Ristamäki, R., Sundström, J. T. T., & Carpén, O. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2240-x · Cited by 89
The Hippo Pathway and Viral Infections
Wang, Z., Lu, W., Zhang, Y., Zou, F., Jin, Z., & Zhao, T. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.03033 · Cited by 81
Canale, M., Petracci, E., Delmonte, A., Bronte, G., Chiadini, E., Ludovini, V., Dubini, A., Papi, M., Baglivo, S., Luigi, N. D., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041047 · Cited by 81
Genome-Scale Methylation Analysis of Circulating Cell-Free DNA in Gastric Cancer Patients
Ren, J., Lü, P., Zhou, X., Liao, Y., Liu, X., Li, J., Wang, W., Wang, J., Wen, L., Fu, W., et al. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvab204 · Cited by 79
Yan, R., Fan, X., Xiao, Z., Liu, H., Huang, X., Liu, J., Zhang, S., Yao, J., An, G., & Ge, Y. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.01.030 · Cited by 73
Norwood, D. A., Montalvan-Sanchez, E. E., Domínguez, R. L., & Morgan, D. R. (2022) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2022.05.001 · Cited by 88
Zhang, L., Li, Q., Yang, J., Xu, P., Xuan, Z., Xu, J., & Xu, Z. (2022) · 癌症:英文版 · doi:10.1002/cac2.12386 · Cited by 79
Dysregulated FGF signalling in neoplastic disorders
Tanner, Y., & Grose, R. P. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.10.012 · Cited by 80
Identifying Cancer Subtypes from miRNA-TF-mRNA Regulatory Networks and Expression Data
Xu, T., Le, T. D., Liu, L., Wang, R., Sun, B., & Li, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152792 · Cited by 80
Kloth, M., Ruesseler, V., Engel, C., Koenig, K., Peifer, M., Mariotti, E., Kuenstlinger, H., Florin, A., Rommerscheidt-Fuss, U., Koitzsch, U., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-309026 · Cited by 73
Namba-Fukuyo, H., Funata, S., Matsusaka, K., Fukuyo, M., Rahmutulla, B., Mano, Y., Fukayama, M., Aburatani, H., & Kaneda, A. (2016) · Oncotarget · doi:10.18632/oncotarget.13130 · Cited by 80
Kang, H. J., Oh, J., Chun, S., Kim, D., Ryu, Y., Hwang, H. S., Kim, S., An, J., Cho, E. J., Lee, H., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.018 · Cited by 77
Qiu, M., He, C., Lu, S.-X., Guan, W., Wang, F., Wang, X., Jin, Y., Wang, F., Li, Y., Shao, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32490 · Cited by 73
Wnt Signaling in Cancer: Not a Binary ON:OFF Switch
Flanagan, D. J., Vincan, E., & Phesse, T. J. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1362 · Cited by 80
“Furthermore, RhoA mutations are recurrent in genomically stable gastric tumours, suggesting they contribute to the invasive phenotype of diffuse gastric tumours [32].”
BackgroundSundar, R., Liu, D. H. W., Hutchins, G. G. A., Slaney, H., Silva, A. N. S., Oosting, J., Hayden, J. D., Hewitt, L. C., Ng, C. C. Y., Mangalvedhekar, A. N., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-320805 · Cited by 82
Hepatoid Adenocarcinoma of the Stomach: Current Perspectives and New Developments
Xia, R., Zhou, Y., Wang, Y., Yuan, J., & Ma, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.633916 · Cited by 82
“related to more adverse bio-behavior than nonamplified tumors, including lower differentiation, greater nerve and vascular invasion, and more significant liver metastasis and is associated with worse prognosis (29, 42, 43).”
BackgroundDhar, S. S., & Lee, M. G. (2021) · Oncotarget · doi:10.18632/oncotarget.27988 · Cited by 83
Cheng, X., Dai, E., Wu, J., Flores, N. M., Chu, Y., Wang, R., Dang, M., Xu, Z., Han, G., Liu, Y., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.07.038 · Cited by 87
Wizenty, J., & Sigal, M. J. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01042-2 · Cited by 106
dendsort: modular leaf ordering methods for dendrogram representations in R
Sakai, R., Winand, R., Verbeiren, T., Moere, A. V., & Aerts, J. (2014) · F1000Research · doi:10.12688/f1000research.4784.1 · Cited by 73
Gastric cancer: genome damaged by bugs
Zhao, Y., Zhang, J., Cheng, A. S. L., Yu, J. Q., To, K. F., & Kang, W. (2020) · Oncogene · doi:10.1038/s41388-020-1241-4 · Cited by 76
Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival
Roh, M. R., Gupta, S., Park, K.-H., Chung, K. Y., Lauss, M., Flaherty, K. T., Jonsson, G. G., Rha, S. Y., & Tsao, H. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.01.024 · Cited by 88
Bartley, A. N., Washington, M. K., Ventura, C. B., Ismaila, N., Colasacco, C., Benson, A. B., Carrato, A., Gulley, M. L., Jain, D., Kakar, S., et al. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw206 · Cited by 82
Kim, S. T., Banks, K. C., Lee, S.-H., Kim, K., Park, J. O., Park, S. H., Park, Y. S., Lim, H. Y., Kang, W. K., Lanman, R. B., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00059 · Cited by 73
Liu, H., Zhang, Z., Wu, N., Guo, H., Zhang, H., Fan, D., Nie, Y., & Liu, Y. (2018) · Genes · doi:10.3390/genes9060303 · Cited by 73
Duan, S., Gong, B., Wang, P., Huang, H., Luo, L., & Liu, F. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9368 · Cited by 81
UBE2C Is a Potential Biomarker of Intestinal-Type Gastric Cancer With Chromosomal Instability
Zhang, J., Liu, X., Yu, G., Liu, L., Wang, J., Chen, X., Bian, Y., Ji, Y., Zhou, X., Chen, Y., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00847 · Cited by 72
Echizen, K., Horiuchi, K., Aoki, Y., Yamada, Y. M. A., Minamoto, T., Oshima, H., & Oshima, M. (2019) · Oncogene · doi:10.1038/s41388-019-0702-0 · Cited by 77
Bladder Cancer in the Genomic Era
Guo, C. C., & Czerniak, B. A. (2019) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0329-ra · Cited by 72
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2014-07-23
- Volume
- 513
- Issue
- 7517
- Pages
- 202-209
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4170219
- OpenAlex
- W2126547130
- Cited by
- 6,498
- References
- 43
- Citations by year
- 2026: 455 · 2025: 481 · 2024: 569 · 2023: 637 · 2022: 620 · 2021: 737 · 2020: 653 · 2019: 554 · 2018: 560 · 2017: 490 · 2016: 398 · 2015: 297 · 2014: 41
- FWCI
- 327.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
- KUMeL Repository (Keimyung University) (submittedVersion, cc-by-nc-nd)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067, R01HG007069, U54HG003079, U54HG003273, R01HG005690)
- National Cancer Institute (P30CA16672, K08CA134931, P50CA098258, U24CA143882, P01CA028842, R01CA180006, U24CA143843, U24CA143840, U24CA143858, U24CA126543, U24CA144025, U24CA143866, U24CA143883, U24CA143845, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA143835, K99CA166729, P30CA008748, P30CA016672, P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Keywords
- gastric adenocarcinoma, molecular classification, Epstein-Barr virus, PIK3CA mutation, DNA hypermethylation, PD-L1, PD-L2, microsatellite instability, chromosomal instability, genome stability, RHOA mutations, aneuploidy, targeted therapy, patient stratification
- MeSH terms
- Adenocarcinoma, Herpesvirus 4, Human, Female, Humans, Male, Mutation, Stomach Neoplasms, Genome, Human, Gene Expression Regulation, Neoplastic, Proteome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.